Tropy

PharmaJet Receives NIH Grant to Evaluate use of Needle-free Intradermal Delivery for HPV Immunization

Retrieved on: 
Tuesday, November 29, 2022
Research, Medical Devices, Medical Supplies, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Cervical cancer, Tropy, Use, Padjadjaran University, UNPAD, N/S, National Cancer Institute, Health, Regulatory affairs, Research, Injection, Death, ID, Cancer, Radiation, NIH, HPV, Ageing, Polio, Woman, Vaccine

The study will compare Tropis intradermal delivery against traditional needle and syringe (N/S) intramuscular administration.

Key Points: 
  • The study will compare Tropis intradermal delivery against traditional needle and syringe (N/S) intramuscular administration.
  • The study, in collaboration with Padjadjaran University (UNPAD) in Indonesia, will begin recruiting approximately 900 girls, aged 9 to 14 years of age in early 2023.
  • This follows PharmaJets preliminary studies evaluating intradermal delivery for HPV vaccines.1 Intradermal administration is already widely used for polio vaccine delivery and has been found to be safe, effective, and immunogenic.
  • Intradermal administration of vaccines can provide benefits for low resource settings including lower costs, increased coverage, and increased acceptability.

On World Polio Day 2022, PharmaJet Announces $1.5 million Grant From USAID to Evaluate Use of Needle-Free Delivery in Routine Polio Immunization

Retrieved on: 
Monday, October 24, 2022
Medical Supplies, Biotechnology, White House, Federal Government, Health, General Health, Pharmaceutical, Medical Devices, Research, Infectious Diseases, Public Policy, Government, Science, LinkedIn, Use, Needle, Tropy, Disease, PATH, Review, Vaccine, Â, Peritonitis, CE marking, U.S. FDA, Jhpiego, IPV, System, Research, Principal investigator, Rotary Foundation, Certification, WHO, N/S, AP United States Government and Politics, Rotary, World, Global Polio Eradication Initiative, Poliovirus, Mantoux, Awareness, Bill & Melinda Gates Foundation, World Health Organization, International development, Injection, Vaccination, Government, USAID, ID, United, Compliance, PQS, Public health

The project will measure vaccine coverage and cost using Tropis ID for fractional inactivated poliovirus vaccine (IPV) delivery compared to standard intramuscular delivery using needle and syringe (N/S).

Key Points: 
  • The project will measure vaccine coverage and cost using Tropis ID for fractional inactivated poliovirus vaccine (IPV) delivery compared to standard intramuscular delivery using needle and syringe (N/S).
  • A preferred approach by healthcare workers and patients1 is needle-free ID delivery using Tropis, which was developed with support from the World Health Organization (WHO) and Bill & Melinda Gates Foundation.
  • On this World Polio Day 2022, we restate our commitment to the Global Polio Eradication Initiative and we are pleased to receive this grant from USAID Development Innovation Ventures.
  • Their advocacy efforts have played a role in decisions by governments to contribute more than $10 billion to the effort.

PharmaJet to Present Latest Research Showing Superior Immunogenicity with Their Needle-free Systems at Five Conferences in October

Retrieved on: 
Tuesday, September 27, 2022
Biotechnology, Pharmaceutical, Medical Supplies, Health, Medical Devices, Infectious Diseases, Clinical Trials, Other Health, Adult, Therapy, Volunteering, Injection, COVID-19, Protamine, RNA transfection, Plasmid, Needle, ID, N/S, Electroporation, Vaccination, Review, Tropy, Cadila Healthcare, Use, Vaccine

Intradermal Needle-free delivered vaccines can induce strong immune response comparable to intramuscular and subcutaneous injection with a fraction of the dose.

Key Points: 
  • Intradermal Needle-free delivered vaccines can induce strong immune response comparable to intramuscular and subcutaneous injection with a fraction of the dose.
  • The presentations may also include data from collaborations including those with:
    1.
  • 3 The low dose Tropis group produced significantly increased B and T cell responses compared to a higher dose IM N/S vaccination.
  • Refer to Instructions for Use to ensure safe injections and to review risks.

WHO selects PharmaJet Needle-free Injection System for Million+ Polio Vaccination Campaign

Retrieved on: 
Wednesday, August 31, 2022
Medical Supplies, Health, Infectious Diseases, General Health, Pharmaceutical, Biotechnology, Partnership, CEO, Technology, Immunization, Program, Vaccination, Vaccine hesitancy, WHO, Emergency Committee for American Trade, World, Injection, Tropy, Use, IHR, Failure, International Health Regulations, Polio, Review, World Health Organization, Vaccine

Over 2.7 million children have been targeted for this program so far using the PharmaJet Tropis NFIS.

Key Points: 
  • Over 2.7 million children have been targeted for this program so far using the PharmaJet Tropis NFIS.
  • The WHO previously introduced needle-free intradermal delivery of inactivated polio vaccine (ID-IPV) using the PharmaJet Tropis NFIS in both Pakistan and Somalia for the immunization of over 3 million children.
  • The PharmaJet Tropis NFIS was selected based on its proven cost savings, ease of training and improved coverage benefits.
  • In June, WHOs thirty-second polio International Health Regulations (IHR) Emergency Committee statement , was convened by the WHO Director-General to review the progress on global eradication of polio.

Video Features PharmaJet Needle-free Polio Immunization Campaign

Retrieved on: 
Tuesday, March 29, 2022
Medical Supplies, Medical Devices, Health, Infectious Diseases, Pharmaceutical, Biotechnology, Risk, LinkedIn, WHO, Vaccination, U.S. FDA, Multimedia, Caregiver, UNICEF, Vaccine, Paralysis, Certification, CEO, Injection, CE marking, Use, Review, Tropy, Child, PQS, System, Immunization

PharmaJet , a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced the release of a video highlighting the recent implementation of a polio vaccination campaign in Somalia.

Key Points: 
  • PharmaJet , a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced the release of a video highlighting the recent implementation of a polio vaccination campaign in Somalia.
  • View the full release here: https://www.businesswire.com/news/home/20220329005060/en/
    The 2018 polio outbreak in Somalia emphasized the risk of paralysis to children in under-immunized populations.
  • In late 2021, in response to that risk, the WHO, UNICEF and local Somalia health authorities launched a campaign to immunize children who missed their polio shots during routine immunization.
  • During the campaign, PharmaJet sought to identify key stakeholder attitudes towards needle-free vaccine delivery and how these might impact coverage rates.

PharmaJet, WHO and BMGF Conduct Somalia Polio Vaccination Campaign

Retrieved on: 
Thursday, October 21, 2021
General Health, Infectious Diseases, Health, Pharmaceutical, Medical Supplies, PQS, LinkedIn, Vaccine, Disease, Certification, Vaccination, Caregiver, Child, Immunization, World Health Organization, World, System, Global Polio Eradication Initiative, Sneakers, Review, UNICEF, CE marking, U.S. FDA, Injection, CEO, Use, Awareness, Bill & Melinda Gates Foundation, WHO, Crying, Tropy, PharmaJet, World Polio Day, PHARMAJET, WORLD POLIO DAY

The PharmaJet needle-free system was chosen for the Somalia campaign because the published data1 demonstrated improved coverage and user preferences.

Key Points: 
  • The PharmaJet needle-free system was chosen for the Somalia campaign because the published data1 demonstrated improved coverage and user preferences.
  • Additionally, fractional dose delivery, enabled by Tropis, provides a cost-saving alternative to traditional delivery methods and can extend limited stocks.
  • Of the healthcare workers surveyed, 100% said that using needle-free injectors could increase vaccination rates.
  • Chris Cappello, President and CEO, PharmaJet, said, We are pleased to be part of the polio immunization efforts in Somalia to eradicate this terrible disease.